Chemomab Therapeutics Ltd. (CMMB)

NASDAQ: CMMB · IEX Real-Time Price · USD
1.130
-0.020 (-1.74%)
At close: Jun 14, 2024, 4:00 PM
1.200
+0.070 (6.19%)
After-hours: Jun 14, 2024, 7:45 PM EDT
-1.74%
Market Cap 15.30M
Revenue (ttm) n/a
Net Income (ttm) -19.34M
Shares Out 13.54M
EPS (ttm) -1.56
PE Ratio n/a
Forward PE 13.00
Dividend n/a
Ex-Dividend Date n/a
Volume 66,794
Open 1.160
Previous Close 1.150
Day's Range 1.090 - 1.200
52-Week Range 0.420 - 1.770
Beta 0.22
Analysts Strong Buy
Price Target 5.67 (+401.77%)
Earnings Date Aug 12, 2024

About CMMB

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 20
Stock Exchange NASDAQ
Ticker Symbol CMMB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for CMMB stock is "Strong Buy." The 12-month stock price forecast is $5.67, which is an increase of 401.77% from the latest price.

Price Target
$5.67
(401.77% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug's Direct Interference with Liver Fibroblast Activation— —Ne...

9 days ago - GlobeNewsWire

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammator...

4 weeks ago - GlobeNewsWire

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

─On Track for Midyear 2024 Topline Data and Late 2024/Early 2025 Open Label Data Readouts from CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PSC), Following Early Completion of Patient Enrol...

5 weeks ago - GlobeNewsWire

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammator...

5 weeks ago - GlobeNewsWire

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

TEL AVIV, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammator...

6 weeks ago - GlobeNewsWire

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflamma...

7 weeks ago - GlobeNewsWire

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Peer-reviewed patient study validates Chemomab's CCL24 as a novel target linked to greater disease severity and higher mortality in systemic sclerosis

2 months ago - GlobeNewsWire

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Chemomab's KOL primary sclerosing cholangitis virtual event on April 10 at 10:00 AM ET will include physician & patient PSC experts & a live Q&A session.

2 months ago - GlobeNewsWire

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Chemomab has gained a new EU patent for CM-101 covering its use in liver diseases including PSC, adding to the robust patent estate in major territories.

2 months ago - GlobeNewsWire

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

─Accelerated Phase 2 CM-101 PSC Trial Timeline with Topline 15-Week Data Now Planned for Midyear 2024 and Topline Open Label Data Expected in Late 2024/Early 2025 ─ ─Cash Runway Extended through End o...

3 months ago - PRNewsWire

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

TEL AVIV, Israel , March 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory ...

3 months ago - PRNewsWire

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

—CM-101 Phase 2 Trial for the Treatment of Primary Sclerosing Cholangitis (PSC) Has Completed Patient Enrollment with Topline Data Expected Midyear 2024— — New CM-101 Patents Granted by Brazil and Isr...

4 months ago - PRNewsWire

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

TEL AVIV, Israel , Feb. 14, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory...

4 months ago - PRNewsWire

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

TEL AVIV, Israel , Feb. 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative ther...

4 months ago - PRNewsWire

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

—Proteomic Analysis of Human Samples Highlights the Unique Role of CCL24 in Activating Key PSC-related Disease Mechanisms Involving Immune Cell Trafficking and HSC Activation, Further Confirming the P...

4 months ago - PRNewsWire

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

—Expected Topline Data Readout Accelerated to Midyear 2024 Following Early Completion of Patient Enrollment in Phase 2 Primary Sclerosing Cholangitis (PSC) SPRING Trial— —CM-101's Unique Dual Anti-Fib...

5 months ago - PRNewsWire

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

--Systemic Sclerosis (SSc) Patient Data Shows High Serum CCL24 Levels Associated with More Severe Manifestations of Disease, Including Pulmonary Arterial Hypertension -- -- Study Reveals that CCL24 Ac...

7 months ago - PRNewsWire

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

—CM-101's Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Has Disease Modifying Potential in this Poorly Treated Condition—  —CM-101's Phase 2 SPRING Trial in PSC is Advancing Towards Complet...

7 months ago - PRNewsWire

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023

— New Proteomic Analyses of Phase 2a Liver Fibrosis Clinical Data Show Consistent and Significant Improvements in Liver-related Pathology Pathways After Treatment with CM-101— —Oral Presentation of Pr...

7 months ago - PRNewsWire

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

— Continued Strong Progress in Advancing CM-101 Phase 2 PSC Trial Towards Completion of Enrollment--On Track for Topline Readout in Second Half of 2024— —Reiterates Guidance that Cash Reserves Are Suf...

7 months ago - PRNewsWire

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

-- Chemomab's ADSs Will Continue to Trade on the Nasdaq Capital Market-- TEL AVIV, Israel , Nov. 6, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) ("Chemomab", or the "Company"), a cli...

7 months ago - PRNewsWire

Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update

TEL AVIV, Israel , Oct. 30, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory...

8 months ago - PRNewsWire

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

TEL AVIV, Israel , Oct. 26, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative the...

8 months ago - PRNewsWire

Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference

-- CM-101's Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Supports Its Disease Modifying Potential in Primary Sclerosing Cholangitis (PSC)--- --CM-101 Phase 2 SPRING Trial in PSC is Advanci...

9 months ago - PRNewsWire

Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Virtual presentation to be available starting on September 11, 2023, at 7 AM Eastern Time TEL AVIV, Israel , Aug. 29, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clin...

10 months ago - PRNewsWire